Search

Your search keyword '"Borrelli F"' showing total 23 results
Start Over Author "Borrelli F" Publisher elsevier bv
23 results on '"Borrelli F"'

1. The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients

Author

Pagano, E., primary, Romano, B., additional, Iannotti, F.A., additional, Parisi, O.A., additional, D’Armiento, M., additional, Pignatiello, S., additional, Coretti, L., additional, Lucafò, M., additional, Venneri, T., additional, Stocco, G., additional, Lembo, F., additional, Orlando, P., additional, Capasso, R., additional, Di Marzo, V., additional, Izzo, A.A., additional, and Borrelli, F., additional

Published
2019
Full Text
View/download PDF

22. Reliability of the revised Cochrane risk-of-bias tool for randomised trials (RoB2) improved with the use of implementation instruction

Author

Francesca Borrelli, Silvia Minozzi, Kerry Dwan, Graziella Filippini, Minozzi, S., Dwan, K., Borrelli, F., and Filippini, G.

Subjects
Randomised controlled trial, medicine.medical_specialty, Epidemiology, business.industry, Data Collection, Risk of bia, Reproducibility of Result, Reproducibility of Results, RoB2, Research Personnel, Judgment, Inter-rater reliability, Systematic review, Bias, Bia, Physical therapy, medicine, Humans, business, Reliability (statistics), Kappa, Human
Abstract

Objective to assess the inter-rater reliability (IRR) of the revised Cochrane risk-of-bias tool for randomised trials (RoB2). Methods Four raters independently applied RoB2 on critical and important outcomes of individually randomized parallel-group trials (RCTs) included in the Cochrane Review “Cannabis and cannabinoids for people with multiple sclerosis.” We calculated Fleiss’ Kappa for multiple raters and time to complete the tool; we performed a calibration exercise on five studies, then we developed an implementation document (ID) specific for the condition, and the intervention addressed by the review with instructions on how to answer the signalling questions of RoB2 tool. We measured IRR before and after the ID adoption Results Eighty results related to seven outcomes from 16 RCTs were assessed. During calibration exercise we reached no agreement for overall judgment (IRR -0.15); IRR for individual domains ranged from no agreement to fair. Mean time to apply the tool was 168.5 minutes per study. Time to complete the calibration exercise and develop the ID was about 40 hours. After the ID adoption ID, overall agreement increased to slightly (IRR 0.11) for the first five studies and moderate (IRR 0.42) for the remaining 11. IRR for individual domains ranged from no agreement to almost perfect. Mean time to apply the tool decreased to 41 minutes. Conclusion RoB2 tool is comprehensive but complex even for high experienced raters. The development of an ID specific for the review may improve reliability substantially.

Published
2022
Full Text
View/download PDF

23. Indian ayurvedic herb, Boerhaavia diffusa as BCPR inhibitor: The story behind the curtains

Author

Nataša Milošević, Larisa Đurić, Maja Milanović, Natasa Milic, Nebojša Pavlović, Nunzio Antonio Cacciola, Francesca Borrelli, Milosevic, N., Milanovic, M., Pavlovic, N., Duric, L., Cacciola, N. A., Borrelli, F., and Milic, N.

Subjects
Medicinal herb, Mitoxantrone, food.ingredient, Abcg2, biology, QSAR, Chemistry, In silico, Organic Chemistry, Pharmacology, Drug design, Intestinal absorption, Analytical Chemistry, Inorganic Chemistry, food, Pharmacokinetics, Herb, Lipophilicity, Molecular docking, medicine, biology.protein, Chronic toxicity, Spectroscopy, medicine.drug
Abstract

Nonprenylated rotenoids isolated from Boerhaavia diffusa are identified as new class of breast cancer resistance protein inhibitors (ABCG2). The recent determination of high-resolution structure of ABCG2 (with chemotherapeutics mitoxantrone or Ko143) enables the investigation of molecular interaction capacities of boeravinones. In this research pharmacokinetic/pharmacodynamic relationship of 17 boeravinones considering their molecular properties, ADMET profile and binding energies for ABCG2 was studied for the first time. All 17 compounds met the requirements of empirical rules for drug-likeness. Based on the obtained results lipophilicity was determined as the key property of boeravinones for the intestinal absorption, total clearance and acute and chronic toxicity in rats while polarity was the limiting factor for blood brain barrier permeation. Both lipophilicity and the fraction of sp3 hybridized carbon atoms influenced the binding affinity of boeravinones to ABCG2 proteins (6XVI and 6FFC) expressed as ChemPLP and GOLD Score. The performed in silico analysis implies that boeravinones could be used as potent safe leads to human ABCG2.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results